Roth Mkm Initiates Coverage on NeuroSense Therapeutics (NASDAQ:NRSN)

Stock analysts at Roth Mkm assumed coverage on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report issued on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Roth Mkm’s price objective would indicate a potential upside of 256.97% from the company’s current price.

NRSN has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. Wall Street Zen raised shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ NRSN opened at $0.84 on Tuesday. The company’s fifty day moving average price is $0.92 and its 200 day moving average price is $1.03. NeuroSense Therapeutics has a 1 year low of $0.68 and a 1 year high of $2.60.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics in the 2nd quarter valued at $54,000. Squarepoint Ops LLC lifted its stake in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares in the last quarter. Finally, Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics in the fourth quarter valued at approximately $77,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.